Primary Dysmenorrhea Clinical Trial
Official title:
A Multi-center, Open-label, Randomized, Controlled, Parallel-group Study to Assess Efficacy and Safety of an Extended Flexible Regimen of the Combined Oral Contraceptive SH T00186D (0.02 mg Ethinylestradiol as Beta-cyclodextrin Clathrate and 3 mg Drospirenone) Compared to the Conventional Regimen of SH T00186D in the Treatment of Primary Dysmenorrhea
Verified date | October 2014 |
Source | Bayer |
Contact | n/a |
Is FDA regulated | No |
Health authority | Germany: Federal Institute for Drugs and Medical Devices |
Study type | Interventional |
The investigational drug SH T00186D is an oral contraceptive. The investigational drug used
in this study contains the estrogen ethinylestradiol (EE) and the progestogen drospirenone
(DRSP).
The aim of the present study is to evaluate efficacy and safety of the investigational drug
in the treatment of menstrual pain (pelvic pain occurring shortly before, at onset, during
menstruation). Two different regimens of intake of the same investigational product will be
compared.
Patients have to undergo 2 -3 Baseline cycles (depending on whether the patient was an OC
user before), during which menstrual pain, bleeding events, and pain killer intake have to
be documented. During this observation period, the intake of hormonal contraceptives is not
allowed. Other contraceptive methods (condoms with spermicide, pessary with spermicide) have
to be used. If the patient is eligible for the study, she will be randomly assigned to one
of the two treatment groups. Treatment group A will take the medication according to an
extended flexible regimen, i.e., tablet intake will be triggered by bleeding events.
Treatment group B will take the study medication in the 24 + 4 days regimen. That means,
tablets to be taken on cycle days 1 - 24 contain the hormone combination, whereas tablets 25
- 28 do not contain any active ingredients, i.e., these are so called placebo tablets.
Treatment will last at least 140 days, but can be prolonged in Treatment Group A depending
of occurrence of menstrual bleeding. The overall study duration will be 10 months for each
patient.
During the whole study period, 5 visits are planned. At Screening and Final examination, a
thorough physical examination and a gynecological examination (including breath palpation
and cervical smear ) will be performed. Blood samples will be taken for safety laboratory
parameters.
Additional examinations can be performed any time, if this becomes necessary for medical
reasons.
Patients will be provided with a patient diary to document the intake of study medication,
any bleeding events and days without bleeding, pregnancy test results, any dysmenorrheic
(menstrual) pain and its intensity and its interference with daily activity, and intake of
pain medication. The pain medication (ibuprofen) will be provided.
Status | Completed |
Enrollment | 223 |
Est. completion date | December 2009 |
Est. primary completion date | December 2009 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 40 Years |
Eligibility |
Inclusion Criteria: - Otherwise healthy female patients with moderate to severe primary dysmenorrhea - Prospective self-rated sum pain score of >/= 8 during the 2 baseline cycles - Age between 18 and 40 years (inclusive) with smoking habits as follows: - between 18 and 30 years of age. daily cigarette consumption not above 10 - above 30 years of age, no smoking Exclusion Criteria: - Current signs of history of any forms of secondary dysmenorrhea - Any concomitant disease of condition that requires any intake of analgesic medication - Occurrence of less than six menstrual cycles before Visit 1 following delivery, abortion, or lactation - Clinically significant depression |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Bayer |
Germany, United Kingdom,
Strowitzki T, Kirsch B, Elliesen J. Efficacy of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primary dysmenorrhoea: an open-label, multicentre, randomised, controlled study. J Fam Plann Reprod He — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of days with dysmenorrheic pain | 140 days | No | |
Secondary | Use of rescue medication | 140 days | No | |
Secondary | Interference with daily activity | 140 days | No | |
Secondary | Number of days: with at least moderate dysmenorrheic pain | 140 days | No | |
Secondary | Number of days with pelvic pain | 140 days | No | |
Secondary | Number of days with dysmenorrheic pain associated with withdrawal bleeding | 140 days | No | |
Secondary | Number of days with dysmenorrheic pain associated with unscheduled bleeding | 140 days | No | |
Secondary | Bleeding patterns | Whole treatment period | Yes | |
Secondary | Assessment of treatment | Whole treatment period | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03608215 -
Neuromodulatary Efficacy of Transcranial Direct Current Stimulation in Severe Refractory Primary Dysmenorrhea
|
N/A | |
Completed |
NCT03594916 -
Efficacy of Transcranial Direct Current Stimulation for Severe Primary Dysmenorrhea
|
N/A | |
Not yet recruiting |
NCT04541134 -
Phase 3 Clinical Trial to Evaluate of the Efficacy and Safety of DW9801 in Patients With Primary Dysmenorrhea
|
Phase 3 | |
Completed |
NCT04083131 -
Sense of Coherence and Primary Dysmenorrhea in High School Girls in Finistere, France
|
||
Not yet recruiting |
NCT05448027 -
Low Versus High Intensity Laser Therapy on Primary Dysmenorrhea
|
N/A | |
Completed |
NCT04662814 -
Extracorporeal Shock Wave Therapy for Dysmenorrhea
|
N/A | |
Recruiting |
NCT05771753 -
Comparison of Core Stabilization and Dynamic Stretching Exercises in Primary Dysmenorrhea
|
N/A | |
Not yet recruiting |
NCT04665661 -
Aerobic Exercise for Primary Dysmenorrhea
|
N/A | |
Completed |
NCT03593850 -
Music for Pain in Primary Dysmenorrhea
|
N/A | |
Completed |
NCT03290066 -
Effectiveness of Kinesiotaping in Primary Dysmenorrhea
|
N/A | |
Completed |
NCT04235595 -
Comparison of the Effects of TENS and CTM on Primary Dysmenorrhea
|
N/A | |
Completed |
NCT05081869 -
Investigation of the Effect of Online Yoga Based Exercise Program on Women With Primary Dysmenorrhea
|
N/A | |
Not yet recruiting |
NCT06398990 -
The Effect of Cognitive Exercise Therapy Approach and Yoga in Adolescents With Dysmenorrhoea
|
N/A | |
Completed |
NCT02026206 -
Low-level Light Therapy for Primary Dysmenorrhea
|
Phase 3 | |
Completed |
NCT05686460 -
Effect of Hegu Point Ice Massage and Music in Dysmenorrhea
|
N/A | |
Not yet recruiting |
NCT06052722 -
The Relationship of Premenstrual Syndrome and Primary Dysmenorrhea With Severity of Temporomandibular Disorders
|
N/A | |
Completed |
NCT04119011 -
Probiotics in Women With Primary Dysmenorrhoea
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05938660 -
Effects of Acupressure at Sanyinjiao Point on Primary Dysmenorrhea Among University Students.
|
N/A | |
Completed |
NCT04856280 -
Kinesiological Taping and Aerobic Exercise in Women With Primary Dysmenorrhea:
|
N/A | |
Completed |
NCT02602522 -
Danshen-Jiang-Fu Granule Prepared by Danshen From Different Producing Areas for Primary Dysmenorrhea
|
Early Phase 1 |